Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)
Clinical trial NCT03964792 · COMPLETED
Trial details
- NCT number
- NCT03964792
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-12
- Primary completion
- 2022-07-28
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.